[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5160 Reported in House (RH)]
<DOC>
Union Calendar No. 629
119th CONGRESS
2d Session
H. R. 5160
[Report No. 119-724]
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 4, 2025
Mr. Smith of New Jersey (for himself, Ms. Matsui, Mr. Bilirakis, Ms.
Pingree, Ms. Tenney, and Mr. Mfume) introduced the following bill;
which was referred to the Committee on Energy and Commerce
July 2, 2026
Additional sponsors: Mrs. Fischbach, Mrs. Dingell, Mr. Gottheimer, Mr.
Aderholt, Ms. Malliotakis, Ms. Castor of Florida, Mr. Garbarino, Ms.
Norton, Mr. Bentz, Ms. Barragan, Mr. Finstad, Ms. Morrison, Mr. Lawler,
Mr. Vindman, Mr. Fitzpatrick, and Ms. Davids of Kansas
July 2, 2026
Reported with an amendment, committed to the Committee of the Whole
House on the State of the Union, and ordered to be printed
[Strike out all after the enacting clause and insert the part printed
in italic]
[For text of introduced bill, see copy of bill as introduced on
September 4, 2025]
_______________________________________________________________________
A BILL
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Stem Cell Therapeutic and Research
Reauthorization Act of 2025''.
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION
PROGRAM.
Section 379B of the Public Health Service Act (42 U.S.C. 274m) is
amended--
(1) by striking ``appropriated $31,009,000'' and inserting
the following: ``appropriated--
``(1) $31,009,000'';
(2) in paragraph (1), as so inserted, by striking the
period at the end and inserting ``; and''; and
(3) by adding at the end the following:
``(2) $33,009,000 for each of fiscal years 2027 through
2031.''.
SEC. 3. CORD BLOOD INVENTORY.
(a) In General.--Section 2(a) of the Stem Cell Therapeutic and
Research Act of 2005 (42 U.S.C. 274k note) is amended by striking ``at
least 150,000 new units of high-quality cord blood'' and inserting ``a
sufficient supply, as determined by the Secretary, of high-quality cord
blood units''.
(b) Application.--Section 2(c) of such Act (42 U.S.C. 274k note) is
amended--
(1) in paragraph (2), by striking ``in perpetuity or''; and
(2) by amending paragraph (5) to read as follows:
``(5) if the Secretary determines through an assessment, or
through petition by the applicant, that a cord blood bank is no
longer operational, does not meet the requirements described in
subsection (d)(4), or does not meet the requirements of section
379(d)(4) of the Public Health Service Act, and as a result may
not distribute the high-quality units, the Secretary may
transfer the units collected pursuant to this section to
another qualified cord blood bank or entity approved by the
Secretary to ensure continued availability of high-quality cord
blood units.''.
(c) Duration of Contracts.--Section 2(d)(4) of such Act (42 U.S.C.
274k note) is amended to read as follows:
``(4) Consideration of best science.--The Secretary shall
take into consideration current scientific and clinical
information in order to maximize the availability of high-
quality cord blood units meeting applicable clinical and
quality standards for transplant when entering into contracts
under this section, or when extending a period of funding under
such a contract under paragraph (2).''.
(d) Inventory Management.--Section 2 of such Act (42 U.S.C. 274k
note) is amended--
(1) by redesignating subsections (e), (f), and (g) and as
subsections (f), (g), and (h), respectively; and
(2) by inserting after subsection (d) the following:
``(e) Inventory Management.--
``(1) In general.--The Secretary shall manage the size and
composition of the National Cord Blood Inventory to maximize
clinical utility, ensure genetic diversity, and promote the
efficient use of resources.
``(2) Considerations.--In carrying out paragraph (1), the
Secretary may--
``(A) on the Secretary's own initiative or upon
petition by a qualified cord blood bank, make
determinations regarding the continued storage of cord
blood units based on the best available scientific and
clinical evidence; or
``(B) prioritize the collection, retention, or
disposition of cord blood units based on scientific,
clinical, or operational considerations that the
Secretary determines to be relevant.''.
(e) Definitions.--Section 2(g) of such Act, as redesignated by
subsection (d)(1) of this section, is amended--
(1) by redesignating paragraphs (4) and (5) as paragraphs
(5) and (6), respectively; and
(2) by inserting after paragraph (3) the following:
``(4) The term `high quality cord blood unit' means a cord
blood unit that meets current industry standards and any
requirements of the Food and Drug Administration.''.
(f) Authorization of Appropriations.--Section 2(h) of such Act, as
redesignated by subsection (d)(1) of this section, is amended by
striking ``fiscal years 2022 through 2026'' and inserting ``fiscal
years 2027 through 2031''.
Union Calendar No. 629
119th CONGRESS
2d Session
H. R. 5160
[Report No. 119-724]
_______________________________________________________________________
A BILL
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.
_______________________________________________________________________
July 2, 2026
Reported with an amendment, committed to the Committee of the Whole
House on the State of the Union, and ordered to be printed